$EVGN

Evogene Schedules First Quarter 2026 Financial Results Release

Evogene announced it will release its first quarter 2026 financial results on Wednesday, May 20, 2026. Following the release, company management will host a conference call at 9:00 AM ET to discuss the results. Evogene specializes in computational chemistry and generative AI for small molecule design in pharmaceutical and agricultural industries, using its ChemPass AI™ technology.

Original reporting
Published May 7, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 7, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Evogene Schedules First Quarter 2026 Financial Results Release — source image
Decision brief

The 30-second read

$EVGNNeutralLow
01

Why it matters

The upcoming earnings are a routine event; unless unexpected news emerges, minimal market disruption is anticipated.

02

Market read

While Evogene operates in promising sectors, its stock's low relevance score indicates limited immediate market impact from this news.

03

What to watch

Potential technological breakthroughs or partnerships announced during the conference call could significantly alter stock trajectory.

Timing: medium

Background

Evogene is a biotech company leveraging AI for small molecule design, serving pharmaceutical and agricultural industries.

Company-level read

Ticker impact

$EVGNNeutralMedium confidence
Context

Primary focus due to scheduled earnings release and company's specialization in AI and pharmaceuticals.

Expected impact

Potential for minor price movement (±5%) around the earnings date, contingent on actual results versus expectations.

Evidence & confidence

The scheduled earnings release is a significant event; however, the neutral sentiment and lack of recent strong catalysts suggest limited immediate impact. Technical indicators and market conditions are not provided, limiting precise prediction.

Market effects

The earnings report could influence biotech and AI sectors, especially companies with similar AI-driven biotech solutions.

Limited regional impact expected; primarily relevant to US and Israeli markets where Evogene operates.

Low; Evogene's market cap and global influence are modest, and the news is company-specific.

Counterpoint

Positive surprise in earnings could lead to a sharp upward move, especially if results surpass expectations.

Key entities

  • Evogene Ltd.

    A biotech firm specializing in computational chemistry and AI-driven solutions for pharma and agriculture.

  • ChemPass AI™

    Evogene's proprietary AI platform for small molecule design.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.